We are interested in developing and understanding injectable materials for tissue engineering and drug delivery applications in a variety of cardiovascular diseases with a particular focus on the heart. With the ultimate goal of clinical translation, we are developing a variety of extracellular matrix (ECM)-derived biomaterials systems to treat acute and chronic myocardial infarction, heart failure, and congenital heart defects. We mainly focus on acellular approaches that are amenable to minimally invasive delivery as well as allow for an off-the-shelf product that can translate to the clinic faster. The first technology developed in the lab, our myocardial matrix hydrogel, is already in clinical trials. We are now exploring less invasive strategies for intracoronary and intravenous infusion of ECM-derived and synthetic materials for treating the heart. 

We are also interested in the use of injectable biomaterials for women's health applications. Women's health research has been traditionally underfunded and limited. Together with Dr. Marianna Alperin, we are applying regenerative engineering and biomaterials strategies for tissue repair and regeneration for a variety of applications in women's health, including pelvic floor disorders and menopause.